{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/management/nail-psoriasis/","result":{"pageContext":{"chapter":{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis","depth":2,"htmlHeader":"<!-- begin field f1126a3f-e3ba-49ba-8759-1a36210a95f5 --><h2>Scenario: Nail psoriasis</h2><!-- end field f1126a3f-e3ba-49ba-8759-1a36210a95f5 -->","summary":"Covers the management of nail psoriasis in primary care.","htmlStringContent":"<!-- begin item 86773683-e790-46e7-a85c-4add88325743 --><!-- begin field 9c69a47f-0c3b-4b64-9ebf-acbc015bb2c2 --><p>From age 18 years onwards.</p><!-- end field 9c69a47f-0c3b-4b64-9ebf-acbc015bb2c2 --><!-- end item 86773683-e790-46e7-a85c-4add88325743 -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"54079799-845c-5b3d-b9e2-e1f0da65b2fa","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 464185aa-65b2-4c1e-a374-508eb78e8aba --><h3>How should I manage nail psoriasis?</h3><!-- end field 464185aa-65b2-4c1e-a374-508eb78e8aba -->","summary":null,"htmlStringContent":"<!-- begin item e6cc0055-4bb0-4799-a9c2-8345fa3ee745 --><!-- begin field abafe0de-58d1-4cbd-9c9d-6853f127ce4b --><p><strong>If the person has suspected <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#nail-psoriasis\">nail psoriasis</a>:</strong></p><ul><li>Provide advice on sources of information and support, such as:<ul><li>The Psoriasis and Psoriatic Arthritis Alliance (PAPAA; website available at <a href=\"http://www.papaa.org/\" target=\"_blank\" data-hyperlink-id=\"e2999b4c-97ed-4319-a069-a93100c79e5b\">www.papaa.org</a>) is a national charity which provides information and advice on all aspects of psoriasis and psoriatic arthritis, including an information leaflet on <a href=\"http://www.papaa.org/sites/default/files/nail%20Psoriasis%20final.pdf\" target=\"_blank\" data-hyperlink-id=\"e5900c93-9f96-42d5-a1f5-a93100c79f5e\">Nail psoriasis</a>.</li><li>The Psoriasis Association (website available at <a href=\"https://www.psoriasis-association.org.uk/\" target=\"_blank\" data-hyperlink-id=\"7850d74d-0d02-473b-b827-a93100c79f67\">www.psoriasis-association.org.uk</a>) is a national charity and membership organization for people affected by psoriasis, which has an information leaflet on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Nails.pdf\" target=\"_blank\" data-hyperlink-id=\"c0fd5bfd-7ab9-4d0c-a7a7-a93100c79f76\">Nails</a>.</li></ul></li><li>Advise the person to:<ul><li>Keep their nails short — this avoids exacerbating onycholysis (detachment of the nail from the nail bed) and reduces the accumulation of material under the nail.</li><li>Avoid manicure of the cuticle — this may provoke paronychia (infection of the nail bed). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/paronychia-acute/\">Paronychia - acute</a> for more information.</li><li>Avoid prosthetic nails.</li></ul></li><li>If nail disease is mild and is not causing discomfort or distress:<ul><li>No treatment is needed.</li><li>Nail varnish can be used to disguise pitting, but the person should avoid abrasive acetone-based nail varnish removers.</li></ul></li><li>If nail disease is severe and having a major functional or cosmetic impact:<ul><li>Consider whether there may be an <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/differential-diagnosis/\">alternative diagnosis</a>, and manage appropriately.</li><li>Arrange referral to a dermatologist for <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#specialist-assessment-management\">specialist assessment and management</a>. Advise the person that improvements in nail psoriasis may lag behind improvements in skin and joint disease (if affected).</li></ul></li></ul><!-- end field abafe0de-58d1-4cbd-9c9d-6853f127ce4b --><!-- end item e6cc0055-4bb0-4799-a9c2-8345fa3ee745 -->","subChapters":[{"id":"963eb715-0a00-5ada-881e-0d9ca02a9a70","slug":"basis-for-recommendation-6c8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1bae34f6-bc00-45b8-bc36-9eaab1ef029b --><h4>Basis for recommendation</h4><!-- end field 1bae34f6-bc00-45b8-bc36-9eaab1ef029b -->","summary":null,"htmlStringContent":"<!-- begin item 6c8c7af8-121b-4c2c-9a71-d8408e3ab3a9 --><!-- begin field 1c91d4a8-38c2-4901-9b28-58ba1b227261 --><p>The recommendations on the management of nail psoriasis are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], a Cochrane systematic review <em>Interventions for nail psoriasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">de Vries, 2013</a>], a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>], a US consensus statement <em>Treatment of nail psoriasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Crowley, 2015</a>], and expert opinion in a review article on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>] and nail psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Edwards and de Berker, 2009</a>].</p><h5>Giving self-care advice</h5><ul><li>The recommendations on self-care advice are based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Edwards and de Berker, 2009</a>].</li></ul><h5>Arranging dermatology referral</h5><ul><li>The recommendations on referral are largely based on the NICE clinical guideline, as topical therapy is unlikely to be effective in nail disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>]. This is supported by expert opinion in the concise guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>].</li><li>A Cochrane systematic review of 18 randomized controlled trials (RCTs; n = 1266) found low-quality evidence for the use of systemic treatments if nail psoriasis is severe, refractory to other treatments, or is having a major impact on the person's quality of life. It concluded that evidence for the use of topical treatments is inconclusive and of poor quality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">de Vries, 2013</a>].</li><li>CKS notes that this contrasts with a US consensus statement recommending high-potency topical corticosteroids with or without a vitamin D analogue as initial treatment options for nail psoriasis, and specialist systemic or biologic therapy may be considered if there is significant nail disease and topical treatments have failed. It notes that poor penetration of topical therapy into the nail and surrounding structures is a challenge in treating nail disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Crowley, 2015</a>].</li></ul><!-- end field 1c91d4a8-38c2-4901-9b28-58ba1b227261 --><!-- end item 6c8c7af8-121b-4c2c-9a71-d8408e3ab3a9 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}